Skip to main content
$1.14 -0.01 (-0.44%)

High

$1.17

Low

$1.13

Trades

1,304

Turnover

$2,983,889

Volume

2,606,681
30 June 2023 at 4:10pm
If you were already registered, log in here.

Short Interest

ASIC data, 9 Nov 2026

% Shorted

7.17% 0.01
vs 7.18% prior report

Most Shorted Rank

40th
of 711 shorted ASX stocks

Peak Short

11.00%
Oct 2015

Days to Cover

28.4
at 50d avg vol
Subject
MSB Ann: MSB Q3 Financial Results and Operational Highlights

MSB Ann: Third Quarter Financial Results on Form 6-K

MSB Ann: Mesoblast Q3 Financial Results Webcast

MSB Ann: Remestemcel-L Survival Outcomes in COVID-19 ARDS Patients

MSB Ann: Ceasing to be a substantial holder

MSB Ann: Becoming a substantial holder

MSB Ann: Litigation Update

MSB Ann: Ceasing to be a substantial holder

MSB Ann: Ceasing to be a substantial holder

MSB Ann: Quarterly Activities/Appendix 4C Cash Flow Report

MSB Ann: Becoming a substantial holder

MSB Ann: Appendix 3G and Appendix 3H

MSB Ann: Company Secretary Appointment

MSB Ann: Becoming a substantial holder

MSB Ann: Initial Director's Interest Notice

MSB Ann: Director Appointment

MSB Ann: S&P DJI Announces March 2022 Quarterly Rebalance

MSB Ann: Final Director's Interest Notice

MSB Ann: MSB Q2 Financial Results and Operational Highlights

MSB Ann: Second Quarter Results Presentation

MSB Ann: Half Yearly Report and Accounts

MSB Ann: Mesoblast Q2 Financial Results Webcast

MSB Ann: Ulcerative Colitis & Crohns Results Presented at ECCO

MSB Ann: Mesoblast Appoints Dr Eric Rose as Chief Medical Officer

MSB Ann: Appendix 4C Quarterly Activity Report

MSB Ann: MSB Presents at Edison Group Global Healthcare Conference

MSB Ann: Cleansing Notice and Appendix 2A

MSB Ann: Proposed issue of securities - MSB

MSB Ann: Appendix 3G, Appendix 3H and Appendix 3Y

MSB Ann: 36-Month Results of Phase 3 Trial in Chronic Low Back Pain

MSB Ann: Biotech Showcase 2022 Presentation

MSB Ann: Prospectus for Warrants Related to Oaktree Debt Refinance

MSB Ann: Update on FDA Meeting for Remestemcel-L in Paediatric GvHD

MSB Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain

MSB Article: Mesoblast shares tank as Novartis terminates deal

MSB Article: ASX overcomes Woolies, Mesoblast sell-off to close flat

MSB Ann: Update on Novartis Agreement

MSB Ann: Pause in Trading

MSB Ann: Rexlemestrocel Greatest Benefit in Diabetics and Ischemics

MSB Ann: Global CardioVascular Clinical Trialists Forum Presentation

MSB Ann: Results of Meeting

MSB Ann: CEO Presentation to 2021 Annual General Meeting

MSB Ann: Mesoblast Chairman Message to 2021 AGM

MSB Ann: MSB Q1 Financial Results and Operational Highlights

MSB Ann: First Quarter Results Presentation

MSB Ann: First Quarter Financial Results on Form 6-K

MSB Ann: Mesoblast Q1 Financial Results Webcast

MSB Ann: MSB and Oaktree Conclude Refinancing of Senior Debt Facility

MSB Ann: Proposed issue of securities - MSB

MSB Article: Mesoblast surge guides ASX to small rise

If you were already registered, log in here.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
OPT
PAR
PYC
RAC
TLX
S88
MAV
ATW $7.5m raise
RDO $30m raise
ABC $5m raise
RGS
MBM